某院2012~2015年口服降糖药使用分析与评价

Analysis and Evaluation of Utilization of Oral Hypoglycemic Agents in A Hospital During 2012-2015

目的评价本院口服降糖药应用情况和变化趋势,为临床合理用药提供科学依据。方法对本院2012~2015年临床应用口服降糖药的品种、销售金额、用药频度（DDDs）、日均费用（DDC）等进行回顾性分析。结果 2012~2015年本院口服降糖药的销售金额总体呈上升趋势,各种口服降糖药的销售金额、DDDs均逐年增加,销售金额排名前3位的是二甲双胍胶囊、罗格列酮片和格列齐特片;DDDs排名前3位的是二甲双胍胶囊、格列齐特片和罗格列酮片;销售金额序与DDDs的排序比在0.67~1.50之间。结论本院口服降糖药的应用基本合理,适当引入新型口服降糖药物可满足不同病情的需要。

OBJECTIVE To evaluate the utilization and trend of oral hypoglycemic agents in the hospital, so as to provide scientific basis for rational application of oral hypoglycemic agents. METHODS By retrospective analysis, the clinical utilization of oral hypoglycemic agents in the hospital during 2012-2015 was collected and analyzed statistically in respect of drug categories, consumption sum, DDDs and DDC, etc. RESULTS The consumption sum of oral hypoglycemic agents in general was on the rise from 2012 to 2015, Sale amount, DDDs of oral hypoglycemic agents were increasing year by year. Metformin capsule, Rosiglitazone tablets and Gliclazide tablets ranked the first three places in consumption sum. The first three places of DDDs were Metformin capsule, Gliclazide tablets and Rosiglitazone tablets. The ratios of sale amount serial number to that of DDDs were between 0.67-1.50. CONCLUSION The clinical utilization of oral hypoglycemic agents in the hospital is generally rational. Appropriate introduction of new type of oral hypoglycemic agents can meet the needs of different conditions.